Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698266 | 0.85 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21569584 | 0.85 | PPARA (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL598460 | 0.84 | CA9 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24169594 | 0.84 | HDAC1 (0.59) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL17746095 | 0.84 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17746094 | 0.84 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8995835 | 0.83 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9713087 | 0.82 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16414537 | 0.82 | GABRA1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2986982 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-24 | — | — | US | disclosed |
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| EP-2209790-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | CA12 4122/4885CA1 4408/4885CA2 3483/4885 |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | CA12 4377/4885CA1 4547/4885CA2 2820/4885 |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | CA12 4122/4885CA1 4408/4885CA2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.